Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs TotalEnergies SE — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while TotalEnergies SE trades at $90 (market cap $197.99B). The key difference: TotalEnergies SE is far larger — about 26.9× Spyre Therapeutics Inc. Common Stock's market cap, and TotalEnergies SE pays a 4.73% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and TotalEnergies SE for 91 Days on average.
| SYRE | TTE | |
|---|---|---|
Market Cap | $7.35B | $197.99B |
Volume | 1,624,631 | 2,678,834 |
Sector | Health | Energy |
52-Week High | $108.92 | $93.60 |
52-Week Low | $22.18 | $60.44 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $6.35B | $228.98B |
Dividend Yield | — | 4.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TotalEnergies (TTE) trades at $88.95, up 0.66% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a P/E of 11.13 and ROE of 14.56%, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent news highlights a $10B investment in Argentina and a $2.5B Q4 buyback increase, signaling aggressive growth plans.
Outlook remains positive with a consensus price target of $95.33, but risks include volatile oil prices and execution of expansion strategies. The company's focus on LNG and power diversification, coupled with a 5% dividend growth target by 2030, offers a balanced opportunity for value investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
